Christopher Rovaldi

2022

In 2022, Christopher Rovaldi earned a total compensation of $4.2M as Chief Operating Officer at Keros Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$235,000
Option Awards$3,538,605
Salary$435,352
Other$38,397
Total$4,247,354
83.31%

Rovaldi received $3.5M in option awards, accounting for 83% of the total pay in 2022.

Rovaldi also received $235K in non-equity incentive plan, $435.4K in salary and $38.4K in other compensation.

Rankings

In 2022, Christopher Rovaldi's compensation ranked 804th out of 5,744 executives tracked by ExecPay. In other words, Rovaldi earned more than 86.0% of executives.

ClassificationRankingPercentile
All
804
out of 5,744
86th
Division
Manufacturing
365
out of 3,128
88th
Major group
Chemicals And Allied Products
123
out of 1,416
91st
Industry group
Drugs
110
out of 1,317
92nd
Industry
Pharmaceutical Preparations
81
out of 963
92nd
Source: SEC filing on April 24, 2023.

Rovaldi's colleagues

We found two more compensation records of executives who worked with Christopher Rovaldi at Keros Therapeutics in 2022.

2022

Jasbir Seehra

Keros Therapeutics

Chief Executive Officer

2022

Simon MBBS

Keros Therapeutics

Chief Medical Officer

News

In-depth

You may also like